Milestones and perspectives in viral hepatitis B

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 129-134

  Hadziyannis, Stephanos J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chronic hepatitis B; Hepatitis B virus; Interferon; Milestones; Nucleoside analogues; Treatment

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; VIRUS DNA;

ARTICLE; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MOLECULAR DIAGNOSIS; MONITORING; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; VIRUS MUTANT;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS;

EID: 78650817009     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02406.x     Document Type: Article

References (85)

1. Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967; 200: 365-73.
2. Blumberg BS, Alter HJ, Visnich S. A 'new' antigen in leukemia sera. JAMA 1965; 191: 541-6.
3. Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-31.
4. Blumberg BS, Sutnick AI, London WT. Australia antigen and hepatitis. JAMA 1969; 207: 1895-6.
5. Giles JP, Mccollum RW, Berndtson LW Jr, et al. Relation of Australia-SH antigen to the willowbrook MS-2 strain. N Engl J Med 1969; 281: 119-22.
6. Almeida JD, Rubenstein D, Stott EJ. New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet 1971; 2: 1225-7.
7. Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis. Nature 1968; 218: 1057-9.
8. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-8.
9. Magnius LO, Espmark A. A new antigen complex co-occurring with Australia antigen. Acta Pathol Microbiol Scand B Microbiol Immunol 1972; 80: 335-7.
10. Magnius LO, Espmark JA. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109: 1017-21.
11. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
12. Hoofnagle JH. Type B hepatitis: virology, serology and clinical course. Semin Liver Dis 1981; 1: 7-14.
13. Lai M, Liaw YF. Chronic hepatitis B: past, present, and future. Clin Liver Dis 2010; 14: 531-46.
14. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.
15. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
16. Sherlock S, Fox RA, Niazi SP, et al. Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet 1970; 1: 1243-7.
17. Szmuness W, Prince AM. Epidemiologic patterns of viral hepatitis in eastern Europe in the light of recent findings concerning the serum hepatitis antigen. J Infect Dis 1971; 123: 200-12.
18. Hadziyannis SJ. Chronic viral hepatitis. Clin Gastroenterol 1974; 3: 391-408.
19. Nordenfelt E. Some epidemiological and clinical aspects of hepatitis B antigen and its subtypes. Scand J Infect Dis 1975; 7: 147-52.
20. Chen DS, Sung JL. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol 1978; 25: 423-30.
21. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978; 24: 40-69.
22. Wewalka F, Hadziyannis S, Pesendorfer FX, et al. OMGE - Study on prevalence of hepatitis B surface antigen in different liver diseases. Scand J Gastroenterol 1979; 56 (Suppl.): 55-68.
23. Hadziyannis SJ. Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol 1980; 9: 117-34.
24. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.
25. Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305: 1067-73.
26. Mcmahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
27. Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619-28.
28. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-81.
29. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
30. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
31. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
32. Prince AM, Trepo C. Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet 1971; 1: 1309-12.
33. Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970; 19: 410-1.
34. Hadziyannis S, Moussouros A, Vissoulis C, et al. Cytoplasmic localisation of Australia antigen in the liver. Lancet 1972; 1: 976-9.
35. Hadziyannis S, Gerber MA, Vissoulis C, et al. Cytoplasmic hepatitis B antigen in 'ground-glass' hepatocytes of carriers. Arch Pathol 1973; 96: 327-30.
36. Ray MB, Desmet VJ, Bradburne AF, et al. Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients. Gastroenterology 1976; 71: 462-9.
37. Bianchi L, Gudat F. Immunopathology of hepatitis B. Prog Liver Dis 1979; 6: 371-92.
38. Ray MB, Desmet VJ, Bradburne AF, et al. Hepatitis B core antigen immune complexes in the liver of hepatitis B patients. Clin Exp Immunol 1979; 37: 15-24.
39. Milich DR. Molecular and genetic aspects of the immune responses to hepatitis B viral antigens. Adv Exp Med Biol 1989; 257: 115-33.
40. Chu CM, Liaw YF. Intrahepatic expression of HBcAg in chronic HBV hepatitis: lessons from molecular biology. Hepatology 1990; 12: 1443-5.
41. Naoumov NV, Portmann BC, Tedder RS, et al. Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990; 99: 1248-53.
42. Brechot C, Tiollais P. [Genetic engineering and the hepatitis B virus]. Gastroenterol Clin Biol 1981; 5: 93-100.
43. Wain-Hobson S, Pourcel C, Brechot C, et al. Structure and expression of the hepatitis B virus genome. Dev Biol Stand 1981; 50: 293-300.
44. Shafritz DA, Lieberman HM. The molecular biology of hepatitis B virus. Annu Rev Med 1984; 35: 219-32.
45. Wands JR, Fujita YK, Isselbacher KJ, et al. Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci USA 1986; 83: 6608-12.
46. Bonino F, Brunetto MR, Smedile A, et al. The impact of molecular biology in the diagnosis and management of viral hepatitis. Ric Clin Lab 1988; 18: 261-71.
47. Pugh JC, Bassendine MF. Molecular biology of hepadnavirus replication. Br Med Bull 1990; 46: 329-53.
48. Milich DR. Immune response to hepatitis B virus proteins: relevance of the murine model. Semin Liver Dis 1991; 11: 93-112.
49. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 24-34.
50. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-15.
51. Billiau A. The mode of action of interferons in viral infections and their possible role in the control of hepatitis B. J Hepatol 1986; 3 (Suppl. 2): S171-179.
52. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-8.
53. Thomas HC, Scully LJ, Mcdonald JA. Lymphoblastoid and recombinant alpha-A interferon therapy of chronic hepatitis B virus infection. The Royal Free Hospital experience. J Hepatol 1986; 3 (Suppl. 2): S193-197.
54. Weller IV, Fowler MJ, Monjardino J, et al. Inhibition of hepatitis B viral replication by lymphoblastoid interferon. Philos Trans R Soc Lond B Biol Sci 1982; 299: 128-30.
55. Dusheiko GM, Paterson AC, Pitcher L, et al. Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials. J Hepatol 1986; 3 (Suppl. 2): S199-207.
56. Hadziyannis SJ, Lieberman HM, Karvountzis GG, et al. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983; 3: 656-62.
57. Lok AS, Hadziyannis SJ, Weller IV, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25: 1283-7.
58. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
59. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268-73.
60. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
61. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
62. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-50.
63. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
64. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-63.
65. Hadziyannis SJ. Anti-HBe positive chronic active hepatitis, 1981; 683. In: Szmuness W, Alter H, Maynard J, eds.Viral Hepatitis Symposium. New York: The Franklin Institute Press.
66. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
67. Lok ASF, Mcmahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Available at (accessed 9 August 2010).
68. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 1995; 22: 42-4.
69. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
70. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
71. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
72. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49: S103-11.
73. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-9.
74. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
75. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
76. Manesis EK, Hadziyannis ES, Angelopoulou OP, et al. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
77. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
78. Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
79. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
80. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
81. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
82. Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006; 45: 355-60.
83. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
84. Hansen BE, Buster EH, Steyerberg EW, et al. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010; 82: 1135-42.
85. Hadziyannis SJ, Sevastianos V, Rapti I. Outcome of HBeAg-negative chronic hepatitis B (CHB) 5 years after discontinuation of long term adefovir dipivoxil (ADV) treatment. J Hepatol 2009; 50 (Suppl. 1): S9-10.